Baird’s Bristol-Myers Squibb BMY Stock Holding History

Baird’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q1	$22.7M	Sell	351,814 -7,276	-2%	-$456K	0.23%	132
2014 Q4	$21.2M	Buy	359,090 +67,923	+23%	+$3.83M	0.23%	140
2014 Q3	$14.9M	Sell	291,167 -12,801	-4%	-$639K	0.21%	133
2014 Q2	$14.7M	Sell	303,968 -305	-0.1%	-$15K	0.21%	129
2014 Q1	$15.8M	Buy	304,273 +7,579	+3%	+$403K	0.23%	130
2013 Q4	$15.8M	Buy	296,694 +35,173	+13%	+$1.79M	0.27%	106
2013 Q3	$12.1M	Buy	261,521 +3,080	+1%	+$135K	0.23%	124
2013 Q2	$11.6M	Buy	+258,441	New	+$11.2M	0.23%	110

Other funds holding BMY

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Baird's BMY Position: Q1 2015 in Review

Baird reduced its Bristol-Myers Squibb (BMY) stake by 2% in Q1 2015, selling an estimated $456K and leaving 351,814 shares worth $22.7M. The position accounts for 0.23% of the portfolio, ranked #132.

Baird first reported a position in BMY in Q2 2013 and has held it in 8 quarters since. 1,449 funds tracked by Wall St. Rank hold BMY as of Q1 2015.

Baird held 351,814 shares of Bristol-Myers Squibb worth $22.7M as of Q1 2015.
Baird sold 7,276 Bristol-Myers Squibb shares in Q1 2015, an estimated $456K.
Bristol-Myers Squibb made up 0.23% of Baird's portfolio in Q1 2015, its #132 holding.
Baird first reported a position in Bristol-Myers Squibb in Q2 2013 and has held it in 8 quarters since.
1,449 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2015.

Based on Baird's 13F filing for Q1 2015, filed 13 May 2015.